These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 25876909)

  • 1. A Novel Partial Agonist of Peroxisome Proliferator-Activated Receptor γ with Excellent Effect on Insulin Resistance and Type 2 Diabetes.
    Liu HJ; Zhang CY; Song F; Xiao T; Meng J; Zhang Q; Liang CL; Li S; Wang J; Zhang B; Liu YR; Sun T; Zhou HG
    J Pharmacol Exp Ther; 2015 Jun; 353(3):573-81. PubMed ID: 25876909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gallic acid attenuates high-fat diet fed-streptozotocin-induced insulin resistance via partial agonism of PPARγ in experimental type 2 diabetic rats and enhances glucose uptake through translocation and activation of GLUT4 in PI3K/p-Akt signaling pathway.
    Gandhi GR; Jothi G; Antony PJ; Balakrishna K; Paulraj MG; Ignacimuthu S; Stalin A; Al-Dhabi NA
    Eur J Pharmacol; 2014 Dec; 745():201-16. PubMed ID: 25445038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel Podophyllotoxin Derivatives as Partial PPARγ Agonists and their Effects on Insulin Resistance and Type 2 Diabetes.
    Zhang X; Liu H; Sun B; Sun Y; Zhong W; Liu Y; Chen S; Ling H; Zhou L; Jing X; Qin Y; Xiao T; Sun T; Zhou H; Yang C
    Sci Rep; 2016 Nov; 6():37323. PubMed ID: 27853282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of PPARγ by Aegle marmelos ameliorates insulin resistance and β-cell dysfunction in high fat diet fed-streptozotocin induced type 2 diabetic rats.
    Sharma AK; Bharti S; Goyal S; Arora S; Nepal S; Kishore K; Joshi S; Kumari S; Arya DS
    Phytother Res; 2011 Oct; 25(10):1457-65. PubMed ID: 21351301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects.
    Chang CH; McNamara LA; Wu MS; Muise ES; Tan Y; Wood HB; Meinke PT; Thompson JR; Doebber TW; Berger JP; McCann ME
    Eur J Pharmacol; 2008 Apr; 584(1):192-201. PubMed ID: 18346728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel PPARα/γ agonist, propane-2-sulfonic acid octadec-9-enyl-amide, ameliorates insulin resistance and gluconeogenesis in vivo and vitro.
    Ren T; Yang WS; Lin Y; Liu JF; Li Y; Yang LC; Zeng KY; Peng L; Liu YJ; Ye ZH; Luo XM; Ke YJ; Diao Y; Jin X
    Eur J Pharmacol; 2018 May; 826():1-8. PubMed ID: 29476879
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ankaflavin: a natural novel PPARγ agonist upregulates Nrf2 to attenuate methylglyoxal-induced diabetes in vivo.
    Lee BH; Hsu WH; Chang YY; Kuo HF; Hsu YW; Pan TM
    Free Radic Biol Med; 2012 Dec; 53(11):2008-16. PubMed ID: 23022408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro.
    Burgermeister E; Schnoebelen A; Flament A; Benz J; Stihle M; Gsell B; Rufer A; Ruf A; Kuhn B; Märki HP; Mizrahi J; Sebokova E; Niesor E; Meyer M
    Mol Endocrinol; 2006 Apr; 20(4):809-30. PubMed ID: 16373399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists on glycemic control, lipid profile and cardiovascular risk.
    Derosa G; Maffioli P
    Curr Mol Pharmacol; 2012 Jun; 5(2):272-81. PubMed ID: 22122457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema.
    Gregoire FM; Zhang F; Clarke HJ; Gustafson TA; Sears DD; Favelyukis S; Lenhard J; Rentzeperis D; Clemens LE; Mu Y; Lavan BE
    Mol Endocrinol; 2009 Jul; 23(7):975-88. PubMed ID: 19389808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.
    Xu Y; Etgen GJ; Broderick CL; Canada E; Gonzalez I; Lamar J; Montrose-Rafizadeh C; Oldham BA; Osborne JJ; Xie C; Shi Q; Winneroski LL; York J; Yumibe N; Zink R; Mantlo N
    J Med Chem; 2006 Sep; 49(19):5649-52. PubMed ID: 16970391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
    Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
    J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614.
    Minoura H; Takeshita S; Ita M; Hirosumi J; Mabuchi M; Kawamura I; Nakajima S; Nakayama O; Kayakiri H; Oku T; Ohkubo-Suzuki A; Fukagawa M; Kojo H; Hanioka K; Yamasaki N; Imoto T; Kobayashi Y; Mutoh S
    Eur J Pharmacol; 2004 Jun; 494(2-3):273-81. PubMed ID: 15212984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential for peroxisome proliferator-activated receptor-gamma agonists in progression: beyond metabolism.
    Fogo AB
    Curr Opin Nephrol Hypertens; 2008 May; 17(3):282-5. PubMed ID: 18408479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.
    Choi WS; Lee JJ; Kim Y; Kim IS; Zhang WY; Myung CS
    Arch Pharm Res; 2011 Apr; 34(4):615-24. PubMed ID: 21544727
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PAR-5359, a well-balanced PPARalpha/gamma dual agonist, exhibits equivalent antidiabetic and hypolipidemic activities in vitro and in vivo.
    Kim MK; Chae YN; Son MH; Kim SH; Kim JK; Moon HS; Park CS; Bae MH; Kim E; Han T; Choi HH; Shin YA; Ahn BN; Lee CH; Lim JI; Shin CY
    Eur J Pharmacol; 2008 Oct; 595(1-3):119-25. PubMed ID: 18727927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time-dependent therapeutic roles of nitazoxanide on high-fat diet/streptozotocin-induced diabetes in rats: effects on hepatic peroxisome proliferator-activated receptor-gamma receptors.
    Elaidy SM; Hussain MA; El-Kherbetawy MK
    Can J Physiol Pharmacol; 2018 May; 96(5):485-497. PubMed ID: 29244961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPAR agonists for the treatment of cardiovascular disease in patients with diabetes.
    Wilding JP
    Diabetes Obes Metab; 2012 Nov; 14(11):973-82. PubMed ID: 22443197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of thiazolidine-2,4-dione/biphenylcarbonitrile hybrid as dual PPAR α/γ modulator with antidiabetic effect: in vitro, in silico and in vivo approaches.
    Hidalgo-Figueroa S; Ramírez-Espinosa JJ; Estrada-Soto S; Almanza-Pérez JC; Román-Ramos R; Alarcón-Aguilar FJ; Hernández-Rosado JV; Moreno-Díaz H; Díaz-Coutiño D; Navarrete-Vázquez G
    Chem Biol Drug Des; 2013 Apr; 81(4):474-83. PubMed ID: 23289972
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.